1. Home
  2. AQB vs ENSC Comparison

AQB vs ENSC Comparison

Compare AQB & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

HOLD

Current Price

$0.92

Market Cap

3.9M

Sector

N/A

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.43

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQB
ENSC
Founded
1991
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
6.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AQB
ENSC
Price
$0.92
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.3K
415.8K
Earning Date
10-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.47
$1.26
52 Week High
$2.95
$10.96

Technical Indicators

Market Signals
Indicator
AQB
ENSC
Relative Strength Index (RSI) 37.46 33.84
Support Level $0.91 $1.26
Resistance Level $1.03 $1.69
Average True Range (ATR) 0.07 0.15
MACD 0.02 -0.01
Stochastic Oscillator 28.11 27.97

Price Performance

Historical Comparison
AQB
ENSC

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: